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AbstrACt
Objectives Thoracotomy is considered one of the 
most painful surgical procedures. The incidence of 
chronic post-thoracotomy pain (CPTP) is up to 50%. 
Paravertebral blockade (PVB) may be superior to thoracic 
epidural blockade (TEB) in preventing CPTP. The speciic 
objective of this pilot study was to assess the feasibility 
of conducting a larger trial to determine whether PVB at 
thoracotomy is more effective in reducing CPTP compared 
with TEB.
Design A randomised, parallel, external pilot study was 
conducted to assess whether a large randomised trial 
of TEB and PVB with CPTP as the primary outcome is 
feasible.
setting Two adult thoracic centres in the UK.
Participants All adult patients admitted for elective open 
thoracotomy. Participants were excluded if they were 
American Society of Anesthesiologists physical status IV 
or V; or if there is contraindication to local anaesthetics; 
infection near the proposed puncture site; coagulation/
thoracic spine disorders; required chest wall resection 
or emergency thoracic surgery or had a previous 
thoracotomy.
results All patients presenting for thoracotomy were 
screened over a 12-month period with 194 found to be 
eligible. Of these, 69 (36%) were randomised (95% CI 29% 
to 42%). Discounting ive participants who died, 54 of 
64 participants (84%) returned questionnaire booklets at 
6 months. The number of participants indicating at least a 
moderate level of chest pain at 6 months was lower with 
PVB but with high levels of uncertainty (RR: 0.7; 95% CI 
0.3 to 1.7 for worst pain; RR: 0.3; 95% CI 0.0 to 2.8 for 
average pain). There were no safety concerns.
Conclusions A large, multicentre randomised controlled 
trial of PVB versus TEB is feasible as it is possible to 
randomise and follow up participants with high idelity. 
Pain scores were lower on average with PVB compared 
with TEB but a much larger trial is required to conirm this 
reliably.
trial registration number ISRCTN45041624
bACkgrOunD
An estimated 7200 thoracotomies (surgical 
incision into the chest wall) are performed 
annually in the UK, most commonly to treat 
lung cancer.1 Thoracotomy is considered one 
of the most painful surgical procedures due 
to tissue, muscle and nerve damage from the 
incision and wound retraction.
Intercostal nerve injury can result in a 
high risk of persistent pain for months after 
surgery.2–4 The incidence of chronic post-tho-
racotomy pain (CPTP; defined as pain that 
recurs or persists at least 2 months following 
the surgery)5 is thought to be as high as 50%.6
strengths and limitations of this study
 Ź This randomised, external, pilot trial had preplanned 
feasibility thresholds to assess whether a large trial 
is feasible.
 Ź Selected two sites represented the national thoracic 
and anaesthetic cohort, providing best representa-
tion of full trial national recruitment.
 Ź Consultant anaesthetists in both participating sites 
had adequate training and appropriate assessment 
for the competence of each technique.
 Ź The study was not designed and powered to be 
large or long enough to provide convincing evidence 
to support the use of either thoracic epidural block-
ade or paravertebral blockade as intraoperative 
anaesthetic technique, but provides evidence that a 
larger, substantive trial is feasible.
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Two main analgesic techniques are commonly used for 
perioperative pain control during thoracotomy. Thoracic 
epidural blockade (TEB) blocks nerves that supply the 
chest with local anaesthetic bilaterally, at spinal cord level. 
It acts by reducing onward transmission of painful nerve 
signals but may not abolish them completely.7 8 Paraverte-
bral blockade (PVB) involves injecting local anaesthetic 
into the paravertebral space, which contains spinal nerves 
(and sometimes even extension of the dura), white and 
grey rami communicantes, the sympathetic chain and 
intercostal vessels, on the side of surgery.9 There are 
studies that describe the spread of PVB injections anteri-
orly across the heads and necks of the ribs to the spaces 
above and below; medially through an intervertebral 
foramen or spread laterally in the intercostal plane.9 
However, compared with TEB, PVB has the potential to 
completely block painful nerve signals from reaching 
the spinal cord.9 10 This total blockade of nerve signals 
could remove the stimulus for ‘central sensitisation’, 
which underpins the formation of chronic pain pathways. 
PVB could be uniquely effective in preventing long-term 
pain,11 and there is evidence from a recent trial of two 
techniques in breast surgery to support this premise.12 
With limited current evidence to support the most effec-
tive choice of anaesthetic technique in preventing CPTP, 
current UK practice varies greatly.13 A recent Cochrane 
review recommended that a high-quality randomised 
controlled trial (RCT) to compare TEB and PVB with the 
primary outcome of chronic pain is urgently needed.14
The overall aim of this research is to determine whether 
PVB at thoracotomy is more effective in reducing CPTP 
compared with TEB. To answer this question, a large, 
multicentre RCT is required. The specific aim of this 
pilot study was to assess the feasibility of conducting a 
larger trial and to enhance the likelihood of its success 
by developing the necessary structure and processes that 
a large trial would need. Objectives included an assess-
ment of the effectiveness of the patient identification and 
screening process; identification of reasons for failure 
to randomise; development of educational and training 
materials for surgeons and anaesthetists; evaluation of 
robustness of in-hospital data collection processes; assess-
ment of trial processes including impact on participants 
and staff.
MethODs
We conducted a randomised, parallel-group, external 
pilot trial of TEB versus PVB for perioperative pain 
control during thoracotomy. Recruitment took place 
over 12 months in two adult thoracic centres: Heartlands 
Hospital, Birmingham and University Hospital South 
Manchester (Wythenshawe, England).
Population and inclusion/exclusion criteria
Eligible participants were all adults admitted for an 
elective open thoracotomy. Participants were excluded 
if they had any of the following: American Society of 
Anesthesiologists (classification of fitness) physical status 
IV or V (as these patients are unlikely to present for elective 
surgery due to their physical condition), contraindication 
to local anaesthetics, infection near the proposed punc-
ture site, coagulation abnormalities (in accordance with 
Association of Anaesthetists in Great Britain and Ireland 
guidance 2013), thoracic spine disorders, required chest 
wall resection or emergency thoracic surgery or had a 
previous thoracotomy (scarring due to previous surgery 
can limit the effectiveness of paravertebral block and 
these patients may have existing chronic pain).
study conduct
All patients thought to fulfil the eligibility criteria were 
approached with study information at their preopera-
tive assessment clinic. They were provided with a Patient 
Information Sheet and given the opportunity to consider 
participation. Once eligibility was confirmed and written 
informed consent was obtained, randomisation was 
performed prior to surgery using a web-based central 
randomisation system (via Birmingham Clinical Trials 
Unit) to allocate patients to either TEB or PVB in a 1:1 
ratio. Minimisation was used to achieve balance between 
sex, age (<65 years or ≥65 years), thoracotomy for lung 
cancer resection or for other indication and study site. 
Research nurses at each site were responsible for rando-
misation and assigned group allocation was revealed to 
responsible anaesthetist when patients arrived at the 
operating theatre. An Oversight Committee was formed 
to provide independent guidance to the Trial Manage-
ment Committee and to review accruing safety informa-
tion during the period of recruitment. Public and patient 
involvement was integral to the study throughout.
Interventions
Interventions were delivered by experienced thoracic 
anaesthetists, trained and deemed competent in both 
anaesthetic techniques. Participants were not told specifi-
cally about their allocated intervention. It was not possible 
to blind anaesthetists, surgeons or nursing staff due 
to the nature of the interventions. PVB was performed 
using three single injections preincision with the patient 
awake or asleep, at the levels of T3–4, 5–6 and 7–8 with 
15 mL 0.25% levobupivacaine/bupivacaine, using a land-
mark technique at each level. The PVB catheter was then 
placed at T5 under direct vision by a surgeon during 
surgery. A loading dose of 10 mL 0.25% levobupivacaine/
bupivacaine was administered before chest closure, 
followed by infusion of 0.125% levobupivacaine/bupiva-
caine 0.1–0.25 mL/kg/hour until end of operation. TEB 
was inserted preincision with the patient awake or asleep, 
with a catheter inserted at the spinal level supplying the 
skin at the incision site (normally T5–6), a test dose of 
3 mL of 0.5% bupivacaine, and a loading dose of 0.25% 
levobupivacaine/bupivacaine 0.1 mL/kg with up to 3 mg 
of diamorphine. This was followed by infusion of 0.125% 
levobupivacaine/bupivacaine with 2 µg/mL fentanyl at 
0.1–0.25 mL/kg/hour. Further information on delivery 
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and training on the interventions is available in the study 
protocol.15 Identical dressings and pumps were used for 
both interventions to maintain group allocation.
Pilot outcomes
The following outcomes and targets were set a priori as 
being indicative that a larger trial would be feasible to 
conduct.15 These were as follows: (1) patient recruitment 
rate (the proportion of eligible patients randomised) 
at least 25%; (2) screening rate (the proportion of all 
patients listed for elective thoracotomy that were screened 
for eligibility and recorded on a screening log) at least 
90%; (3) clinicians’ willingness to recruit: national survey 
of consultant thoracic anaesthetist indicating the number 
willing to participate in a larger study at least 70%; (4) 
data completion—number of anaesthetic/perioperative 
forms completed at least 90% and follow-up question-
naires completed at 6 months at least 80%. The study 
was given a 12-month recruitment period, after which 
screening would stop.
Clinical and participant-reported outcome measures
Baseline data (including participant completed questions 
as indicated below) were recorded at the preoperative 
assessment appointment. Intraoperative (anaesthetic 
technique and use), postoperative and discharge data 
(analgesic use, pain scores on days 1–3, acute compli-
cations, mortality and length of stay) were collected by 
the study team. Three-month and 6-month post-rando-
misation follow-up was conducted by postal question-
naire. This included Visual Analogue Scales (VAS)16 
for worst and average chest pain (overall, at rest, after 
coughing, after moving, after physiotherapy; with higher 
score—maximum 10—indicating higher levels of pain, as 
marked along a 10 cm line), Brief Pain Inventory (BPI),17 
Neuropathic Pain Scale (NPS),18 generic health-related 
quality of life (EQ-5D-5L),19 Hospital Anxiety and Depres-
sion Scale20 and assessment of satisfaction and partic-
ipant blinding. Serious adverse events were collected 
throughout. Patient outcome data were collected by a 
research team member who was blinded to the assigned 
group.
statistics
We expected to recruit between 50 and 75 participants 
over a 12-month recruitment period, depending on the 
number found to be eligible. We estimated that there 
would be approximately 500 open elective thoracoto-
mies from the two sites, of which 60% would potentially 
be eligible (300). Using our own target criteria of 25% 
recruited would yield 75 participants. This number would 
be sufficient to measure the recruitment rate to uncer-
tainty width up to approximately 10%.
Feasibility outcomes were considered with simple 
summary statistics (proportions and percentages), with 
uncertainty estimates provided by 95% CIs. Clinical and 
participant-reported outcome measures were analysed 
with point estimates (RR or mean difference) and 95% 
CIs, adjusting for the minimisation variables. They were 
not subject to hypothesis testing as the size of the sample 
would not allow reliable assessment of efficacy.21 Partici-
pants were considered in the groups they were randomised 
to regardless of compliance (intention-to-treat).
Qualitative assessment and survey of practice
In addition to the clinical assessment, semistructured 
qualitative interviews were undertaken with 18 patients 
at 6–8 weeks discharge to gauge the impact of the trial 
on their hospital care and eight clinical staff (four anaes-
thetists, one surgeon and three members of the research 
team) to aid insight into trial-related processes. Patients 
who were recruited to the trial were asked if they would 
be willing to be interviewed about their experiences of 
being in the trial. Those who consented to be interviewed 
were contacted by the qualitative researcher to arrange a 
telephone interview. The name and contact details of staff 
who had been involved in the trial and were willing to be 
interviewed were provided to the qualitative researcher, 
and an interview was arranged. The patient and staff tele-
phone interviews were audiorecorded and field notes 
were taken in order to capture the interviewer’s thoughts 
subsequent to completing each interview. Audiorecord-
ings were transcribed in full by an experienced team of 
professional transcribers, with transcripts subsequently 
proof read against the recordings by the researcher. Anony-
mised transcripts were analysed thematically concurrently 
with data collection in order to allow emerging findings 
to be included in subsequent interviews.22 The resulting 
codes and themes were refined, and consistency and 
variation across the interviews were explored. Once this 
process was completed, the resulting themes generated 
from the data were summarised. The main themes for 
patient interviews included the acceptability of the trial; 
motivations for being involved in the trial; experiences 
of participating in the trial—for example, did patients 
feel well informed about what involvement would entail; 
thoughts about the questionnaires used to assess levels of 
pain. The main themes from the staff interviews included 
experiences of patient identification and screening, expe-
riences of the randomisation process and reflections on 
the trial in general terms—what processes went well and 
were there any areas for improvement. An electronic 
national survey of anaesthetists on willingness to partic-
ipate in a future trial was also conducted via the Associ-
ation for Cardiothoracic Anaesthesia and Critical Care 
membership in 26 UK thoracic units.
Patient involvement
Our study question in chronic pain post thoracotomy is 
in the top-ranked research priorities voted by patients: 
‘What can we do to stop patients developing chronic 
pain after surgery?’ The development of study protocol 
was designed in conjunction with our patient partners 
who also participated as a member of trial management 
group and trial steering committee. Our patient partners 
reviewed study design, paying attention to acceptability 
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of randomisation analgesic techniques in perioperative 
setting and burden of study participation. Study results 
including plan for future study has been disseminated 
within local and national patient research ambassador 
groups.
results
Participants and follow-up
Five hundred sixty-four patients were screened for eligi-
bility from July 2015 to July 2016—100% of those listed 
for elective thoracotomy—with 194 patients found to be 
eligible (figure 1). The most common reasons for inel-
igibility were undergoing video-assisted thoracoscopic 
surgery (VATS) (174/370, 47%); participation in another 
study which did not allow co-enrolment (59/370, 16%) 
and previous thoracotomy (31/370, 8%). Of the 194 
patients, 69 (36%, 95% CI 29% to 42%) were ultimately 
randomised. Of the others, the most common reasons for 
non-randomisation were anaesthetists trained to perform 
PVB not available (23/125, 19%); did not want to be 
randomised (15/125, 12%) and patient had preference 
for PVB (15/125, 12%). Details of randomised partici-
pants are given in table 1. The minimisation algorithm 
provided appropriate balance for the balancing factors; 
the average age of participants was 66 years with the vast 
majority were having a lung cancer resection operation 
Figure 1 Flowchart of patients through the study.
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Table 1 Baseline characteristics of patients
PVB (n=35) TEB (n=34)
Age ≥65, years* 21 (60) 20 (59)
Age, years Mean (SD) 66.0 (10.6) 65.9 (7.9)
Gender=male* 19 (54) 20 (59)
Centre* Birmingham Heartlands 23 (66) 26 (76)
University Hospital South Manchester 12 (34) 8 (24)
Reason for thoracotomy is lung cancer resection* 30 (86) 30 (88)
ASA physical status 1. Normal healthy 0 (−) 2 (6)
2. Mild systemic disease 13 (37) 10 (30)
3. Severe systemic disease 22 (63) 21 (64)
Missing – 1
ECOG performance status 0. Normal activity 20 (57) 19 (58)
1. Symptomatic but nearly fully ambulatory 14 (40) 14 (42)
2. Symptomatic but bed <50% daytime 1 (3) 0 (−)
3. Symptomatic bed >50% daytime 0 (−) 0 (−)
4. Unable to get out of bed 0 (−) 0 (−)
Missing – 1
Dyspnoea 0. None 17 (48) 17 (52)
1. Slight 16 (46) 13 (39)
2. Moderate 2 (6) 1 (3)
3. Moderately severe 0 (−) 2 (6)
4.Severe 0 (−) 0 (−)
5. Very severe 0 (−) 0 (−)
Missing – 1
Smoking status Never smoked 7 (20) 6 (18)
Stopped >1 year 19 (54) 18 (55)
Stopped >6 weeks 3 (9) 3 (9)
Stopped <6 weeks 1 (3) 4 (12)
Current smoker 5 (14) 2 (6)
Missing – 1
Smoking-pack years Median (IQR) 37 (20, 49) 37 (20, 50)
Missing – 1
Alcohol units per week Median (IQR) 3 (0, 13.5) 0 (0, 9.7)
Missing – 1
Previous medical history=yes COPD 7 (20) 6 (18)
Ischaemic heart disease 4 (11) 3 (9)
Congestive cardiac failure 0 (−) 1 (3)
Hypertension 18 (51) 15 (45)
Diabetes diet controlled 0 (−) 3 (9)
Diabetes oral medication 6 (17) 3 (9)
Diabetes insulin controlled 2 (6) 1 (3)
Renal failure 1 (3) 1 (3)
Previous stroke 0 (−) 0 (−)
Hyperthyroidism 0 (−) 0 (−)
Hypothyroidism 5 (14) 2 (6)
Other cancer 12 (34) 7 (21)
Chronic pain 2 (6) 5 (15)
Missing – 1
BMI, kg/m2 Mean (SD) 28.4 (5.8) 27.7 (5.9)
Missing – 1
Frequency (%) presented (unless otherwise stated).
*Minimisation variable.
ASA, American Society of Anesthesiologists; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; PVB, paravertebral blockade; TEB, thoracic epidural 
blockade.
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(60/69, 87%). Seven participants (10%) reported previous 
problems with (unspecified) chronic pain.
At 6 months post randomisation, 54 of 63 (86%) ques-
tionnaire booklets were returned, discounting five partic-
ipants who died during the follow-up period and one 
participant who withdrew from the study. Of these, only 
one did not complete their VAS questions.
Analgesic technique
Of the 69 randomised, 67 (97%) received their 
randomised intervention. One participant allocated PVB 
received TEB as the pleura was removed and the surgeon 
was unable to place the PVB. Another participant was 
not considered fit for surgery and was withdrawn from 
the study. Discounting these participants, all anaesthetic 
technique and intraoperative forms were completed. A 
summary of the anaesthetic techniques is given in table 2; 
a summary of the operative details and other analgesics 
provided to participants up to discharge is provided in 
the online supplementary appendix tables S1 and S2.
Patient-reported outcomes
Levels of pain in the 3 days post operation appeared similar 
in both groups (see online supplementary appendix 
table S3). The number of patients indicating at least a 
moderate level of average or worst chest pain (based on 
commonly used threshold of >3 or ≥423 24) was lower with 
PVB compared with TEB at 6 months, but with expected 
high levels of uncertainty given the limited size of sample 
(table 3; full results given in online supplementary 
appendix table S4). Results from other questionnaire 
responses had a lot of uncertainty (table 4).
safety
No concerns were expressed by the independent Over-
sight Committee who met twice during the recruitment 
period to review study progress and safety data. Compli-
cations and short-term mortality data appeared similar in 
both groups (see online supplementary appendix table 
S5). There were five deaths; only one was considered to be 
a serious adverse event—this was aspiration pneumonitis 
and was not considered related to intervention (PVB). 
One other participant experienced a serious adverse 
event in the TEB group; this participant was diagnosed 
with acute kidney injury in the postoperative period.
Assessment of participant blinding
Nineteen of thirty-two (60%) patients in the TEB group 
correctly identified the anaesthetic technique they had 
been allocated at discharge and the figure for PVB was 
8/31 (26%); this reduced to 13/24 (52%) in the TEB 
group at 6 months and 5/26 (19%) in the PVB group 
(see online supplementary appendix table S6).
national survey of anaesthetists
Forty-three responses were returned. Of these, 27 anaes-
thetists indicated that they would be willing to randomise 
in a future study (63%). Five (12%) indicated that they 
would ‘possibly’ be willing to randomise with reasons of 
Table 2 Anaesthetic technique summary
PVB (n=35) TEB (n=33)*
Dificulty in insertion 4 (12)† 14 (42)
Failure to deliver technique 1 (3) 0 (−)
Intraoperative use
Preoperative bolus given 26 (74) 25 (76)
Bolus drug given through catheter 14 (40) 24 (73)
Infusion given through catheter 23 (66) 21 (64)
Postoperative settings
Local anaesthetic was Bupivacaine (as 
opposed to Levobupivacaine)
32 (94)† 19 (58)
Concentration 0.1% 20 (59)† 11 (33)
0.125% 4 (12)† 22 (67)
0.25% 10 (29)† 0 (−)
Fentanyl None 32 (91) 3 (9)
2 μg/mL 0 (−) 0 (−)
4 μg/mL 3 (9) 30 (91)
Starting rate, mL/hour Median (IQR) 20 (10, 20)† 6 (6, 8)
Prescribed range, mL/hour Median (IQR) 20 (15, 20)† 12 (8, 15)
Frequency (%) presented (unless otherwise stated).
*One participant received neither technique as operation was not performed for the patient.
†One response is missing (n=34).
PVB, paravertebral blockade; TEB, thoracic epidural blockade.
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concern given as lack of skill and ward structure. The 
remaining 11 (26%) were unwilling.
Qualitative interviews
Interviewed participants had a positive experience, 
reporting that they felt well informed by trial staff. The 
consent process was felt to be well undertaken, and 
patients felt reassured by the explanations of randomis-
ation. A substantial number of participants reported that 
the study questionnaires were long and repetitive. Inter-
viewed staff felt recruitment was successful although there 
were some challenges when the role was undertaken by 
non-clinical staff. There was a feeling that some of the 
data collection tools were repetitive. Clinical staff were 
supportive of the trial; they found that the trial processes, 
randomisation and procedures were very straightforward. 
The guidance and teaching provided for anaesthetists to 
get them up to speed for performing PVB was very posi-
tively received, and it was considered a relatively simple 
procedure to learn.
DIsCussIOn
Our four key indicators for feasibility were met, and we 
have shown that a large multicentre RCT of PVB versus 
TEB for perioperative pain control with an objective of 
assessing long-term post-thoracotomy chronic pain is 
feasible. It is possible to randomise and follow-up patients 
with high fidelity over 6 months. In the qualitative assess-
ment we carried out, participants and staff were largely 
happy with study processes. In particular, the consent, 
randomisation and assessment methods were considered 
appropriate. As hypothesised, VAS pain scores were lower 
with PVB compared with TEB at 6 months on average but 
with high levels of uncertainty. This would need to be 
investigated further in a much more substantial trial.
While the evidence on short-term outcomes, for 
example, minor complications and analgesic efficacy, 
point to PVB being at least as effective as TEB,14 current 
evidence on whether PVB is more effective than TEB in 
reducing rates of chronic pain is limited. A recent system-
atic review failed to attain sufficient data to compare 
the impact of TEB and PVB techniques on CPTP.14 
The incidence of CPTP was very poorly reported, and 
studies did not describe how data on chronic pain were 
measured or collected. The lack of evidence highlights 
an area in need of further research. We are not aware of 
any current or planned randomised trials with CPTP as 
an outcome that may change these findings since this 
systematic review was published. Incidence of CPTP was 
slightly lower in our study—between 30% and 34%—
than previously quoted at 49%,6 although we need to 
acknowledge that our figure is associated with a reason-
ably large amount of uncertainty given the small size of 
sample. A likely contributing factor to this discrepancy 
is the considerable and widely acknowledged variation 
in how pain is measured,25 as it is dependent on the 
measurement instrument and threshold chosen among 
other factors.23
This feasibility work has allowed us to fine-tune study 
processes ahead of a larger trial. One likely modification 
to the future study protocol is to revise the length of the 
follow-up questionnaires, as the participants considered 
that their length was too long and repetitive in content. 
Shortened and simplified follow-up questionnaire would 
also potentially help to improve follow-up figures further, 
as lengthy questionnaires are a known predictor of partic-
ipant drop-out from trials.26
Inclusion and exclusion criteria appeared appropriate 
and do not appear to be changed. The vast majority of 
ineligible participants were those scheduled to receive 
VATS. While this procedure is becoming more popular,1 
the comparison in question is not an appropriate one as 
TEB is not routinely used to provide pain relief in this 
type of surgery. Also, the VATS approach does not require 
any rib spreading, resulting in a less invasive procedure, 
and while chronic pain is still an issue after VATS, it is not 
considered to be as great as following open thoracotomy.27 
Unfortunately, while VATS is becoming more common, 
there will still be a substantial proportion of patients who 
will always be ineligible for this operation because of, for 
example, inability to achieve complete resection in more 
advanced pulmonary lung cancers. Lung cancer remains 
the most common cancer worldwide.28 29
Table 3 Incidence of signiicant (>3 or ≥4) or severe pain 
(≥7) from Visual Analogue Scale scores
PVB
n (%)
TEB
n (%) RR (95% CI)*
Average chest pain overall >3
  3 months 5/25 (20.0) 6/21 (28.6) 0.7 (0.2 to 2.0)
  6 months 2/27 (7.4) 5/25 (20.0) 0.4 (0.1 to 1.7)
Average chest pain overall ≥4
  3 months 5/25 (20.0) 4/21 (19.0) 1.1 (0.3 to 3.4)
  6 months 1/27 (3.7) 3/25 (12.0) 0.3 (0.03 to 2.8)
Average chest pain overall ≥7
  3 months 0/25 (−) 2/21 (10.0) –†
  6 months 0/27 (−) 1/25 (4.0) –†
Worst chest pain overall >3
  3 months 9/24 (37.5) 7/23 (30.4) 1.2 (0.6 to 2.8)
  6 months 7/27 (25.9) 11/26 (42.3) 0.6 (0.3 to 1.3)
Worst chest pain overall ≥4
  3 months 8/24 (33.3) 7/23 (30.4) 1.1 (0.5 to 2.5)
  6 months 7/27 (25.9) 9/26 (34.6) 0.75 (0.3 to 1.7)
Worst chest pain overall ≥7
  3 months 6/24 (25.0) 5/23 (21.7) 1.2 (0.4 to 3.3)
  6 months 2/27 (7.4) 5/26 (19.2) 0.4 (0.1 to 1.8)
*RR <1 indicates less incidence with PVB.
†Unable to estimate.
PVB, paravertebral blockade; RR, relative risk; TEB, thoracic 
epidural blockade.
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Table 4 Results of patient-reported outcomes
PVB mean score (SD, n) TEB mean score (SD, n)
Difference between group means 
(95% CI)
BPI results summary*
  Pain severity score (0–10, higher=worse pain)
    Baseline 0.9 (1.7, 34) 1.3 (2.0, 32) −0.4 (−1.3 to 0.5)
    24 hours post surgery 5.3 (1.7, 33) 3.9 (2.7, 32) 1.4 (0.3 to 2.5)
    48 hours post surgery 5.2 (1.7, 30) 5.1 (2.5, 31) 0.1 (−0.9 to 1.2)
    72 hours post surgery 4.9 (1.7, 23) 5.6 (2.0, 25) −0.7 (−1.8 to 0.4)
    Discharge 4.0 (1.4, 31) 4.1 (2.4, 32) −0.1 (−1.1 to 0.9)
    3 months 1.6 (1.7, 22) 2.5 (2.5, 21) 0.9 (−2.2 to 0.4)
    6 months 1.3 (1.8, 25) 2.3 (2.6, 23) −1.0 (−2.3 to 0.3)
  Pain interference score (0–10, higher=worse pain)
    Baseline 0.6 (1.3, 34) 1.5 (2.2, 32) −0.9 (−1.8 to 0.1)
    24 hours post surgery 5.8 (2.1, 30) 5.4 (2.9, 28) 0.4 (−0.8 to 1.8)
    48 hours post surgery 6.0 (2.0, 30) 5.8 (2.2, 27) 0.2 (−0.9 to 1.3)
    72 hours post surgery 5.4 (2.3, 21) 5.8 (2.6, 23) −0.4 (−1.9 to 1.1)
    Discharge 4.7 (2.0, 23) 4.3 (2.5, 29) 0.4 (−0.9 to 1.7)
    3 months 1.1 (1.4, 24) 2.8 (3.0, 22) −1.7 (−3.1 to 0.3)
    6 months 1.6 (2.2, 27) 1.9 (2.5, 25) −0.3 (−1.6 to 1.0)
NPS results summary*
  How intense does your pain feel? (0–10, higher=worse pain)
    Baseline 1.7 (2.8, 33) 1.8 (2.8, 33) −0.1 (−1.5 to 1.3)
    Discharge 5.8 (2.8, 31) 5.4 (3.8, 31) 0.4 (−1.3 to 2.1)
    3 months 2.2 (2.4, 25) 3.6 (3.8, 21) −1.4 (−3.4 to 0.5)
    6 months 2.2 (2.7, 27) 2.7 (3.2, 26) −0.5 (−2.2 to 1.1)
  How sharp does your pain feel? (0–10, higher=worse pain)
    Baseline 1.1 (2.8, 33) 1.6 (3.4, 32) −0.5 (−2.1 to 1.1)
    Discharge 5.5 (3.2, 31) 5.4 (4.0, 31) 0.1 (−1.7 to 1.9)
    3 months 2.6 (3.0, 25) 3.2 (4.0, 21) −0.6 (−2.8 to 1.5)
    6 months 3.0 (3.3, 27) 2.4 (3.3, 26) 0.6 (−1.3 to 2.4)
  How hot does your pain feel? (0–10, higher=worse pain)
    Baseline 1.0 (2.6, 33) 1.3 (2.7, 32) −0.3 (−1.6 to 1.0)
    Discharge 3.6 (3.4, 31) 2.4 (2.9, 31) 1.2 (−0.4 to 2.8)
    3 months 1.6 (2.8, 25) 2.5 (3.3, 21) −0.9 (−2.7 to 1.0)
    6 months 1.2 (2.0, 28) 1.6 (2.9, 26) −0.4 (−1.7 to 1.0)
  How dull does your pain feel? (0–10, higher=worse pain)
   Baseline 1.8 (2.9, 33) 1.5 (2.5, 33) 0.3 (−1.0 to 1.7)
    Discharge 2.9 (2.7, 30) 3.9 (2.8, 30) −1.0 (−2.4 to 0.5)
    3 months 2.6 (2.1, 25) 3.3 (3.3, 21) −0.7 (−2.4 to 0.9)
    6 months 2.1 (2.8, 28) 2.3 (2.8, 26) −0.2 (−1.8 to 1.2)
  How cold does your pain feel? (0–10, higher=worse pain)
    Baseline 0.3 (1.6, 33) 0.4 (1.7, 32) −0.1 (−0.9 to 0.7)
    Discharge 1.5 (2.5, 30) 1.0 (2.2, 31) 0.5 (−0.7 to 1.7)
    3 months 0.2 (0.5, 25) 1.5 (2.9, 21) −1.3 (−2.7 to 0.0)
    6 months 0.3 (0.9, 28) 0.7 (1.6, 26) −0.4 (−1.1 to 0.3)
  How sensitive is your pain? (0–10, higher=worse pain)
    Baseline 0.5 (1.9, 33) 1.1 (2.5, 32) −0.6 (−1.7 to 0.5)
    Discharge 2.3 (2.9, 30) 2.8 (2.9, 32) −0.5 (−1.9 to 1.0)
    3 months 2.2 (3.0, 25) 2.1 (2.7, 23) 0.1 (−1.6 to 1.7)
Continued
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PVB mean score (SD, n) TEB mean score (SD, n)
Difference between group means 
(95% CI)
    6 months 1.6 (2.0, 28) 2.5 (3.1, 26) −0.9 (−2.4 to 0.5)
  How itchy is your pain? (0–10, higher=worse pain)
    Baseline 0 (0, 33) 0.8 (2.0, 32) −0.8 (−1.5 to 0.0)
    Discharge 2.2 (2.8, 30) 2.6 (3.3, 31) −0.4 (−2.0 to 1.2)
    3 months 1.2 (2.5, 25) 1.8 (2.6, 22) −0.6 (−2.1 to 0.9)
    6 months 0.4 (0.7, 28) 2.1 (2.6, 25) −1.7 (−2.8 to 0.6)
  How unpleasant is your pain? (0–10, higher=worse pain)
    Baseline 1.9 (2.9, 31) 2.1 (3.3, 33) −0.2 (−1.7 to 1.4)
    Discharge 6.2 (3.0, 30) 5.6 (3.3, 30) 0.6 (−1.1 to 2.2)
    3 months 2.8 (2.6, 24) 4.0 (3.9, 21) −1.2 (−3.3 to 0.8)
    6 months 2.4 (2.7, 28) 3.0 (3.2, 24) 0.6 (−2.3 to 1.0)
  How intense is your deep pain? (0–10, higher=worse pain)
    Baseline 1.3 (2.4, 32) 2.4 (3.7, 33) −1.1 (−2.6 to 0.5)
    Discharge 6.2 (2.8, 31) 5.5 (3.4, 31) 0.7 (−0.9 to 2.3)
    3 months 3.0 (2.8, 23) 4.1 (3.7, 21) −1.1 (−3.1 to 0.9)
    6 months 2.8 (3.0, 28) 2.5 (2.9, 25) 0.3 (−1.4 to 1.9)
  How intense is your surface pain? (0–10, higher=worse pain)
    Baseline 0.8 (2.1, 31) 0.7 (1.5, 32) 0.1 (−0.9 to 1.0)
    Discharge 3.9 (3.4, 30) 3.8 (3.3, 32) 0.1 (−1.7 to 1.7)
    3 months 1.9 (2.2, 24) 3.5 (3.6, 21) −1.6 (−3.3 to 0.2)
    6 months 1.2 (1.5, 27) 2.7 (3.2, 24) −1.5 (−2.9 to 0.1)
EQ-5D-DL results summary†
  EQ-5D index score (−0.59=worst outcome, 1.0=best outcome)
    Baseline 0.75 (0.22, 35) 0.77 (0.20, 33) −0.02 (−0.12 to 0.08)
    Discharge 0.49 (0.23, 27) 0.49 (0.23, 30) −0.00 (−0.12 to 0.12)
    3 months 0.73 (0.17, 25) 0.65 (0.23, 23) 0.08 (−0.04 to 0.20)
    6 months 0.72 (0.23, 25) 0.69 (0.22, 25) 0.03 (−0.09 to 0.16)
  EQ-5D thermometer (0–100, higher=better)
    Baseline 76.6 (16.3, 34) 74.3 (17.8, 33) 2.3 (−5.9 to 10.7)
    Discharge 60.4 (22.7, 26) 60.2 (20.7, 30) 0.2 (−11.5 to 11.9)
    3 months 73.2 (21.2, 25) 67.5 (18.3, 23) 5.7 (−5.8 to 17.2)
    6 months 78.0 (14.0, 25) 64.4 (20.4, 25) 13.6 (3.6 to 23.6)
HADS results summary‡
  Depression index score (0–21, lower=better)
    Baseline 2.9 (2.9, 33) 3.0 (2.6, 32) −0.1 (−1.4 to 1.3)
    Discharge 4.3 (3.4, 28) 6.0 (5.0, 28) −1.7 (−4.0 to 0.5)
    3 months 3.6 (2.7, 25) 5.5 (4.0, 21) −1.9 (−4.1 to 0.1)
    6 months 4.5 (3.5, 24) 6.0 (4.6, 25) −1.5 (−3.9 to 0.8)
  Anxiety index score (0–21, 0-lower=better)
    Baseline 6.3 (5.0, 34) 6.5 (4.4, 30) −0.2 (−2.6 to 2.1)
    Discharge 5.0 (4.4, 29) 7.0 (5.3, 28) −2.0 (−4.6 to 0.6)
    3 months 5.2 (4.3, 25) 6.1 (4.8, 19) −0.9 (−3.7 to 1.9)
    6 months 5.7 (3.6, 24) 7.3 (5.0, 25) −1.6 (−4.1 to 0.9)
*Scores<0 indicate less pain with PVB.
†Scores>0 indicate better QoL with PVB.
‡Scores<0 indicate less anxiety/depression with PVB.
BPI, brief pain inventory; HADS, hospital anxiety and depression index score; NPS, Neuropathic Pain Scale; PVB, paravertebral blockade; QoL, 
quality of life; TEB, thoracic epidural blockade. 
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It was apparent from the assessment of the ability to 
blind the participant to the analgesic technique that 
complete blinding is unlikely to be possible. Substantially, 
more participants appeared to be able to determine they 
had had an epidural blockade than the paravertebral 
technique. Attempts to completely blind participants in 
any future study are likely to make processes prohibitively 
complex and expensive due to innate differences in the 
mode of delivery and action in the two analgesic tech-
niques. This could include sham insertion techniques 
to disguise the randomised intervention. The question 
is whether patient blinding is likely to be an important 
potential cause of detection bias, unduly affecting the 
results of any future trial. The proposed primary outcome 
of pain rating is subjective in nature, and this is a theoret-
ical possibility. However, we believe that there is no reason 
to suspect that recipients of the randomised interventions 
have strong preconceptions with regard to the relative 
effectiveness of each analgesic technique. Furthermore, 
the primary outcome would be collected via question-
naires administered by post or phone, at a time remote 
from the original operative procedure, which are likely to 
be resilient to the effects of imperfect concealment.
Findings from the survey of practice were encouraging; 
while we set a target of 70% of thoracic anaesthetists 
willing to randomise to a future trial as being indicative of 
success, we found 63% willing and 12% ‘possibly willing’. 
To achieve 70%, we would require solutions for those 
anaesthetists expressing uncertainty. The major reasons 
given were lack of skill and ward structure. These hurdles 
do not appear insurmountable if funding for further 
training and extra nurse support could be provided; 
something a large funding body may be willing to provide. 
A successful trial would also require full engagement with 
anaesthetic and thoracic surgical trainees’ network to 
maximise recruitment.
We have reported the study to randomised pilot study 
standards as recommended by Consolidated Standards 
of Reporting Trials extension for pilot study.30 Also, as 
recommended,31 we set objectives a priori to determine 
whether the pilot study would demonstrate feasibility of 
a larger trial. Since this study was not a definitive trial, 
we have been careful not to overinterpret the findings. 
Hence at this stage, we cannot expect the outcomes of 
this pilot study to be directly translated into clinical care, 
as the study was not large enough to be able to detect 
small-to-moderate realistic-sized difference in rates of 
chronic pain, nor was the scope wide enough in terms of 
the number of centres involved to return a generalisable 
result.
Nevertheless, this pilot study is an important precursor 
to a larger, substantive, trial and provides invaluable 
information that will help to ensure its success. A defin-
itive study—instigated by the authors of this manu-
script—has now been funded by the National Institute 
of Health Research (NIHR) Health Technology Assess-
ment Programme and is expected to start recruiting in 
2018 from 20 UK thoracic centres. The design of this 
study has been partially informed by the results of this 
pilot. The primary outcome will be incidence of chronic 
pain at 6 months attained from VAS responses similar to 
that used here; other outcomes will follow Initiative on 
Methods, Measurement, and Pain Assessment in Clinical 
Trials (IMMPACT) recommendations.32 A total sample 
size of 1026 participants will give 90% power (p=0.05) 
to detect a reduction in incidence of CPTP of 30% with 
TEB (a similar event rate to that noted in this pilot study) 
down to 20% with PVB. The rate of recruitment noted 
in this study has been factored into the number of sites 
and length of the recruitment period required; we esti-
mate access to a pool of 5000 participants over a two-and-
a-half year recruitment period and need to recruit a fifth 
of these. The design will allow a definitive answer to this 
important question.
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